Earlier quoted context omitted.
> The problem is that cost and risk of development and trials is too large for the current rewards, This kind of invesment has been traditionally done by governments. But with a reduction of taxation governments do not have animore money to do this. And for private companies it makes more sense to spend that kind of money in advertisment than in developing new products. > ensuring good prices or bounties for successf…
> But with a reduction of taxation I’m pretty sure government tax revenue is still at or near all time highs. As the population grows there’s more and more taxes to spend for this purpose. It’s just a matter of priorities.
The antimicrobial resistance crisis needs action now
101–110 of 182 posts
Re: The antimicrobial resistance crisis needs action now
#102We need more research in bacteriophages. They can be engineered to avoid any resistance, and they can replace antibiotics in all use cases. Besides, they are much more selective. Getting antibiotics when needed is OK, but they can lead to other health complications down the road.
I genuinely believe that ideological and political stigma still stands in the way of phage research and use in the West as it did in the cold war when phages were considered "Soviet". More thoughts on this - https://www.theguardian.com/science/2019/may/09/cold-war-pol....
Soviets, Russian and Georgian scientists did a lot of good work; I'm ashamed to see it shunned in Western medicine when I know it can already be effective and save lives if an industry developed around the medical use of phages. Lives lost to antibiotic resistance in the West will be the price of politicizing science.
More on the normality of clinical phage use in the Soviet Union and Eastern Europe - https://www.tandfonline.com/doi/pdf/10.1586/14789072.2.6.815.
Re: The antimicrobial resistance crisis needs action now
#103Earlier quoted context omitted.
The problem with phages is that our immune system can recognize them easily and flush them out of the body. It doesn't stick around long enough to do the work. It could work if the dose is massive or if the infection is localized to one specific area. Btw this is what I learnt from reading a blog from someone who has worked with this stuff. I'm not a biologist and it's been a long time since I read that article so I…
> The problem with phages is that our immune system can recognize them easily and flush them out of the body. The problem with phages is that they are finicky to administer. There is no "get this phage and it will kill all bacteria in and around you" treatment. They are specific. This of course has its own benefits too, but makes the process of administering harder. With antibiotics the doctor comes to the conclusion…
Also as an aside, physics is easier than biology. Once you figure out a solution that works, it always works in the future. The moon is not actively changing its orbit to survive. Bacteria or cancer for that matter always end up finding a way to overcome
Re: The antimicrobial resistance crisis needs action now
#104I am quite sure, that if a sufficient bounty was given out for developing new kinds of antimicrobials, they'd be developed in no time. The problem is that cost and risk of development and trials is too large for the current rewards, and hence there is very little new antimicrobials being developed. There are very many promising leads though, and either making development cheaper (by requiring smaller or fewer clinica…
If that is so, then that research should be done by the state. The well-being of entire human race cannot be tied to monetary incentives of profiteering.
Re: The antimicrobial resistance crisis needs action now
#105I am quite sure, that if a sufficient bounty was given out for developing new kinds of antimicrobials, they'd be developed in no time. The problem is that cost and risk of development and trials is too large for the current rewards, and hence there is very little new antimicrobials being developed. There are very many promising leads though, and either making development cheaper (by requiring smaller or fewer clinica…
> The problem is that cost and risk of development and trials is too large for the current rewards, This kind of invesment has been traditionally done by governments. But with a reduction of taxation governments do not have animore money to do this. And for private companies it makes more sense to spend that kind of money in advertisment than in developing new products. > ensuring good prices or bounties for successf…
This has been the case for decades, yet we still seem to have not learned this.
This is my observation, from having seen this happen in a couple of industries, and hearing of it happening in others.
There seems to be a "sweet spot," in new money-making stuff, where real value is produced, rewards are reaped, and scamming is low.
The industry starts off with small-scale passion projects, and relatively low rewards. Virtually no scamming, but also modest financial gains, as the passion-players start to establish the infrastructure.
Then it starts to "catch on," and a more professional approach is applied. The industry starts to scale, and the first folks on the upswing start to make some good money.
Then, after that, the scale goes up exponentially, the quality of the work nosedives, the rewards pile up, and the scamming becomes more prevalent. Many of the originators fall down, because they can't adapt to the new darwinian order.
Eventually, the whole thing becomes so corrupted, that it collapses under its own weight.
Rinse and repeat.
Re: The antimicrobial resistance crisis needs action now
#106I am quite sure, that if a sufficient bounty was given out for developing new kinds of antimicrobials, they'd be developed in no time. The problem is that cost and risk of development and trials is too large for the current rewards, and hence there is very little new antimicrobials being developed. There are very many promising leads though, and either making development cheaper (by requiring smaller or fewer clinica…
> The problem is that cost and risk of development and trials is too large for the current rewards, and hence there is very little new antimicrobials being developed If that is so, then that research should be done by the state. The well-being of entire human race cannot be tied to monetary incentives of profiteering.
Re: The antimicrobial resistance crisis needs action now
#107Earlier quoted context omitted.
> The problem is that cost and risk of development and trials is too large for the current rewards, and hence there is very little new antimicrobials being developed If that is so, then that research should be done by the state. The well-being of entire human race cannot be tied to monetary incentives of profiteering.
What are examples of the state actually achieving a research objective better than free enterprise?
Re: The antimicrobial resistance crisis needs action now
#108Earlier quoted context omitted.
> The problem is that cost and risk of development and trials is too large for the current rewards, and hence there is very little new antimicrobials being developed If that is so, then that research should be done by the state. The well-being of entire human race cannot be tied to monetary incentives of profiteering.
What are examples of the state actually achieving a research objective better than free enterprise?
Re: The antimicrobial resistance crisis needs action now
#109Earlier quoted context omitted.
What are examples of the state actually achieving a research objective better than free enterprise?
I’m not sure, but what about the space program in the 1960s?
But the space program, and maybe the Manhattan project, actually had real, credible competition, even if it wasn't economic, so maybe were able to escape the bureaucratic trap. Something less urgent (even if it is on paper) like antibiotic resistance, I'm not convinced presents the kind of competition that would actually substitute for a competitive market.
Re: The antimicrobial resistance crisis needs action now
#110Earlier quoted context omitted.
This is actually completely right. I believe there's some policy in the works in the US after talking to a friend who's doing some consulting work to help align the Cost-Benefit side of antimicrobial development. I can't say if there's a plethora of drugs just waiting to be released after CT requirements are lowered, but definitely there is less of an R&D incentive currently because pts who take antimicrobials only t…
There’s also pharma world wide. Seems the system is broken if only massive economic upside in the US is what leads to drug discovery and successful clinical trials.
I actually think this is good since it means we postpone usage of, and thereby resistance to, any new antibiotics.